Loading…
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $15.1B | $3.0B | $1.5B | $1.7B | 13.7% | -2.1% | 42.7% |
| 2024 | $15.5B | $2.5B | $1.0B | $1.3B | 10.7% | 0.1% | -38.1% |
| 2023 | $15.4B | $3.2B | $1.7B | $2.7B | 14.8% | 3.3% | -19.4% |
| 2022 | $14.9B | $3.3B | $2.1B | $2.1B | 10.3% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 14,950 | 15,444 | 15,455 | 15,124 |
| Operating Revenue | - | 14,950 | 15,444 | 15,455 | 15,124 |
| Cost Of Revenue | - | 6,665 | 6,801 | 6,496 | 6,332 |
| Gross Profit | - | 8,285 | 8,643 | 8,959 | 8,792 |
| Operating Expense | - | 5,597 | 6,150 | 6,330 | 6,077 |
| Selling General And Administration | - | 5,633 | 6,141 | 6,329 | 6,088 |
| Total Expenses | - | 12,262 | 12,951 | 12,826 | 12,409 |
| Operating Income | - | 2,688 | 2,493 | 2,629 | 2,715 |
| Total Operating Income As Reported | - | 2,675 | 2,512 | 1,841 | 2,414 |
| EBITDA | - | 3,281 | 3,175 | 2,468 | 2,986 |
| Normalized EBITDA | - | 3,335 | 3,221 | 3,308 | 3,333 |
| EBIT | - | 2,637 | 2,548 | 1,846 | 2,429 |
| Interest Income | - | 0 | 108 | 53 | 51 |
| Interest Expense | - | 0 | 358 | 431 | 430 |
| Net Interest Income | - | 0 | -250 | -378 | -379 |
| Other Non Operating Income Expenses | - | 3 | -7 | 4 | 10 |
| Other Income Expense | - | -51 | -53 | -836 | -337 |
| Interest Income Non Operating | - | 0 | 108 | 53 | 51 |
| Interest Expense Non Operating | - | 0 | 358 | 431 | 430 |
| Net Non Operating Interest Income Expense | - | 0 | -250 | -378 | -379 |
| Pretax Income | - | 2,637 | 2,190 | 1,415 | 1,999 |
| Tax Provision | - | 573 | 526 | 385 | 529 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -11.72 | -11.04 | -228.55 | -91.83 |
| Net Income Continuous Operations | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Net Income From Continuing And Discontinued Operation | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Net Income From Continuing Operation Net Minority Interest | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Net Income | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Net Income Common Stockholders | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Net Income Including Noncontrolling Interests | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Normalized Income | - | 2,106.28 | 1,698.96 | 1,641.45 | 1,725.17 |
| Diluted NI Availto Com Stockholders | - | 2,064 | 1,664 | 1,030 | 1,470 |
| Basic Average Shares | - | 1,888.97 | 1,846 | 1,915 | 1,917 |
| Diluted Average Shares | - | 1,888.97 | 1,850 | 1,923 | 1,924 |
| Reconciled Depreciation | - | 644 | 627 | 622 | 557 |
| Reconciled Cost Of Revenue | - | 6,665 | 6,801 | 6,496 | 6,332 |
| Total Unusual Items | - | -54 | -46 | -840 | -347 |
| Total Unusual Items Excluding Goodwill | - | -54 | -46 | -840 | -347 |
| Special Income Charges | - | -13 | 19 | -767 | -301 |
| Gain On Sale Of Business | - | - | 0 | 0 | 17 |
| Other Special Charges | - | -7 | 26 | 4 | 5 |
| Write Off | - | 12 | 0 | 22 | 23 |
| Impairment Of Capital Assets | - | 0 | - | 556 | 0 |
| Restructuring And Mergern Acquisition | - | 0 | -45 | 185 | 290 |
| Gain On Sale Of Security | - | -41 | -65 | -73 | -46 |
| Gain On Sale Of Ppe | -22 | -8 | 9 | -6 | - |
| Other Operating Expenses | - | -36 | 9 | 22 | -11 |
| Otherunder Preferred Stock Dividend | - | 632 | - | - | - |
| Earnings From Equity Interest | 0 | - | - | - | - |
| Other Taxes | - | 0 | 0 | -21 | 0 |
Consumer Defensive sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Kenvue Inc.this co. | KVUE | $32.4B | 22.05↓ discount | 3.01 | 13.7% | 13.40 |
| Archer-Daniels-Midland Company | ADM | $40.2B | 37.27 | 1.77 | 4.7% | 16.05 |
| The Kroger Co. | KR | $38.4B | 37.77 | 6.47 | 17.1% | 10.37 |
| The Hershey Company | HSY | $37.1B | 41.96 | 7.99 | 19.0% | 21.55 |
| Sysco Corporation | SYY | $35.6B | 19.45 |
| - |
| - |
| - |
| - |
| 19.43 |
| 99.9% |
| 11.84 |
| Kimberly-Clark Corporation | KMB | $31.4B | 15.52 | 20.88 | 134.6% | 12.17 |
| The Estée Lauder Companies Inc. | EL | $30.0B | - | 7.76 | -29.3% | 250.27 |
| The Kraft Heinz Company | KHC | $26.6B | -4.56 | 0.64 | -14.0% | -12.82 |
| Bunge Global SA | BG | $25.1B | 30.77 | 1.58 | 5.1% | 16.16 |
| Peer Median | - | 30.77 | 7.12 | 11.1% | 14.11 | |